Medication Profile · Updated November 2026

Zepbound (Tirzepatide): Cost, Dosing, and Weight Loss Results in 2026

Zepbound is tirzepatide, the same molecule that is in Mounjaro. The difference is the FDA label: Zepbound is approved specifically for chronic weight management, while Mounjaro is approved for type 2 diabetes. I take tirzepatide myself (prescribed as Mounjaro) and have tracked my results with DEXA scans for over a year. This page covers what Zepbound costs, how the dosing works, what the clinical trial data shows, and where to get it at the best price in 2026.

If you want to compare Zepbound to other GLP-1 medications, see our full four-drug comparison.

Quick Facts

How Zepbound Works

Zepbound contains tirzepatide, a dual GIP/GLP-1 receptor agonist. It activates two gut hormones simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).

GLP-1 slows gastric emptying (food stays in your stomach longer, so you feel full), suppresses appetite signals in the brain, and improves insulin sensitivity. This is the same target that Ozempic and Wegovy hit.

GIP adds a second mechanism. It further reduces appetite and appears to play a role in how your body metabolizes and stores fat. This dual approach is what sets tirzepatide apart from semaglutide, which only works on GLP-1.

The practical result: stronger appetite suppression and more weight loss than single-action GLP-1 drugs. The SURMOUNT-5 head-to-head trial confirmed this: 20.2% weight loss with tirzepatide versus 13.7% with semaglutide at 72 weeks.

Zepbound is the only tirzepatide product with an FDA approval for weight management. If your primary goal is weight loss and you do not have type 2 diabetes, Zepbound is the on-label option. For how the diabetes and obesity labels compare across all four brands, see diabetes vs weight-loss GLP-1 dosing. Mounjaro contains the same drug but has the diabetes indication.

For more on how GLP-1 drugs affect body composition, see our guide on fat loss vs weight loss on GLP-1s.

Dosing Schedule

The Zepbound label starts everyone at 2.5 mg once weekly for 4 weeks, then 5 mg. After that, the dose can go up in 2.5 mg steps after at least 4 weeks on the current dose. The table below shows the fastest schedule the label allows. Many people stay at a dose longer, and you do not have to reach 15 mg.

From my experience on tirzepatide: do not expect much from the 2.5 mg starting dose. The real appetite effects begin at 5 mg. Side effects (nausea especially) tend to flare for the first week after each increase, then settle down. Eating slowly, drinking plenty of water, and keeping meals smaller during transition weeks helps a lot.

Your prescriber decides when, or whether, to move you up. Do not raise the dose on your own. Do not use Zepbound if you or a family member has had medullary thyroid carcinoma or MEN 2, and tell your prescriber if you are pregnant or planning a pregnancy, or have had pancreatitis or kidney problems.

For our dosing walkthrough with tips at each level, read the Mounjaro Dosage Guide (same molecule, same doses). If your prescriber will not move you up, here is how to handle a stalled dose increase.

Weight Loss Results: What the Clinical Trials Show

Zepbound’s approval was based on the same SURMOUNT trial program that generated the Mounjaro data. Since the molecule is identical, the results apply to both drugs.

SURMOUNT-1

Published in the New England Journal of Medicine (2022). It studied 2,539 adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, without diabetes. The figures below are the treatment-regimen results from the Zepbound label and the SURMOUNT-1 paper.

At 72 weeks, the 15 mg group lost an average of 20.9% of their body weight. The often-quoted 22.5% figure is the same trial analyzed only among people who stayed on treatment. For someone starting at 250 pounds, 20.9% is roughly 52 pounds.

SURMOUNT-5 (Head-to-Head vs Semaglutide)

This was the trial that really put Zepbound on the map. SURMOUNT-5 was an open-label trial that compared the maximum tolerated dose of tirzepatide (10 or 15 mg) against semaglutide (1.7 or 2.4 mg) over 72 weeks in 751 adults with obesity but without type 2 diabetes.

Results:

• Tirzepatide: 20.2% body weight loss
• Semaglutide: 13.7% body weight loss

Tirzepatide produced roughly 47% more weight loss than semaglutide in a direct comparison (20.2 divided by 13.7). This is the strongest evidence for choosing tirzepatide over semaglutide if both are accessible and affordable for you.

Keep in mind these are averages. Some people respond better to one drug than the other. Your individual results will depend on dose, diet, exercise, genetics, and treatment duration.

For a look at what the scale is not telling you about your weight loss, read our guide on fat loss vs weight loss on GLP-1s.

What Zepbound Costs in 2026

Zepbound has more pricing tiers than most GLP-1 medications because Eli Lilly offers a direct-pay option alongside the standard pharmacy route. Here is the full breakdown.

Brand-Name Zepbound (Pharmacy)

Single-dose Zepbound pens bought at a retail pharmacy without insurance or a savings program cost the list price, which is far higher than the LillyDirect self-pay price. We could not confirm the current list price on Lilly’s pricing page on Nov 4, 2026. For the full breakdown across 90 cash-pay programs, see our 2026 GLP-1 Cash-Pay Pricing Index.

Lilly Direct-Pay Program

Eli Lilly sells Zepbound self-pay through LillyDirect without insurance. Single-dose vials launched first. The 4-dose KwikPen is now sold at the same self-pay prices (checked Nov 4, 2026).

Vials require you to draw the medication with a syringe. The KwikPen holds 4 weekly doses and needs pen needles. Government program beneficiaries (Medicare, Medicaid, TRICARE, VA) are generally excluded from the self-pay offer, except through the Medicare GLP-1 Bridge described below.

With Insurance

Commercial coverage for Zepbound’s weight management use depends on your plan, and many plans still exclude weight-loss drugs. Medicare Part D plans can cover Zepbound for sleep apnea. For weight management, the Medicare GLP-1 Bridge lets eligible Part D enrollees get the Zepbound KwikPen for $50 a month from July 1, 2026 through December 31, 2027, with prior authorization. Single-dose pens and vials are not included.

If your commercial plan covers Zepbound, Lilly offers a savings card that can lower your copay if you meet its terms (LillyDirect). Your copay depends on your plan.

For a full walkthrough of the insurance process, read our GLP-1 insurance coverage guide.

Compounded Tirzepatide

Compounded tirzepatide was the cheap option while tirzepatide was in shortage. The FDA declared the shortage resolved in October 2024 and confirmed that decision in December 2024, and the grace periods for compounders ended February 18, 2025 (503A pharmacies) and March 19, 2025 (503B facilities). Compounded versions are not FDA-approved, and routine copies of an approved drug are no longer permitted. With Zepbound self-pay now $299 to $449/month, the price gap is much smaller than it used to be. Our compounded tirzepatide page covers the details.

For a detailed comparison, see our compounded vs brand-name GLP-1 guide. Compounded vials are dosed in syringe units that depend on concentration, which my tirzepatide units chart walks through.

Pricing Summary

More details in our cheapest GLP-1 options guide and our GLP-1 without insurance guide.

Where to Get Zepbound Online: Providers and Published Prices

These are telehealth providers in our directory that prescribe tirzepatide. Some prescribe brand-name Zepbound and some offer compounded tirzepatide, which is not FDA-approved. Prices are program prices and may not include the medication.

Prices in this table are from our provider directory and can change. Check each provider’s own site before you sign up. Ro, for example, prescribes brand-name Zepbound and bills the drug separately from its membership fee.

For the full provider list with current pricing, visit our provider comparison directory. For the cheapest options specifically, see our cheapest GLP-1 guide.

Common Side Effects

Most side effects are gastrointestinal and worst during dose increases. The rates below are from the weight-loss trials in the Zepbound label, comparing the 5 mg, 10 mg, and 15 mg doses with placebo.

Most common:

• Nausea (25% to 29% across doses, versus 8% on placebo). This is the side effect people talk about most. In my experience, it was manageable. It hit hardest in the first five to seven days after each dose increase, then faded.
• Diarrhea (19% to 23%, versus 8% on placebo). More common at higher doses.
• Vomiting (8% to 13%, versus 2% on placebo).
• Constipation (11% to 17%, versus 5% on placebo). The opposite GI issue. Extra fiber, water, and walking help. More in my constipation relief guide.
• Decreased appetite. The intended effect, but it can feel intense early on. Make sure you are still getting enough protein. Ask your clinician or a dietitian what daily target fits you.
• Injection site reactions. Mild redness or itching at the injection spot. Usually temporary.
• Fatigue. Some people feel tired, especially when eating significantly less in the first weeks at a new dose.

Serious side effects (rare):

• Pancreatitis (seek immediate medical attention for severe, persistent abdominal pain)
• Gallbladder problems (rapid weight loss increases the risk of gallstones)
• Thyroid C-cell tumors (observed in animal studies, boxed warning on label)
• Hypoglycemia (higher risk when combined with insulin or sulfonylureas)
• Kidney injury from dehydration after vomiting or diarrhea
• Not for use during pregnancy

Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

For a detailed guide on managing these effects, see our GLP-1 side effects guide.

How Zepbound Compares to Other GLP-1 Drugs

Zepbound vs Mounjaro: Same drug. Same molecule. Same doses. Zepbound is FDA-approved for weight management. Mounjaro is approved for type 2 diabetes. Your choice between them comes down to your diagnosis and which one your insurance covers. See our Mounjaro vs Zepbound breakdown.

Zepbound vs Wegovy: Different molecules, different mechanisms. Zepbound (tirzepatide, dual GIP/GLP-1) outperformed Wegovy (semaglutide, GLP-1 only) in the SURMOUNT-5 head-to-head trial: 20.2% versus 13.7% weight loss. Wegovy has cardiovascular outcome data in people without diabetes from the SELECT trial. Tirzepatide’s outcome trial so far, SURPASS-CVOT, was in people with type 2 diabetes and compared it with another diabetes drug rather than placebo. See our Zepbound vs Wegovy comparison and full four-drug comparison.

Zepbound vs Ozempic: Zepbound works on two receptors. Ozempic works on one. Zepbound is approved for weight loss. Ozempic is approved for type 2 diabetes. It is sometimes prescribed off-label for weight loss. If maximum weight loss is your goal and you have access to both, tirzepatide is the stronger option based on current evidence. Full details in our Mounjaro vs Ozempic comparison.

If you hit a plateau on tirzepatide, check out our guide: Mounjaro Weight Loss Plateau.

Frequently Asked Questions

What is the difference between Zepbound and Mounjaro?

They contain the same molecule (tirzepatide) at the same doses, made by the same company (Eli Lilly). The only difference is the FDA-approved indication. Zepbound is approved for chronic weight management in adults with obesity or overweight. Mounjaro is approved for type 2 diabetes. Your doctor will prescribe one based on your diagnosis and insurance.

Is Zepbound covered by insurance?

Coverage is expanding but not universal. Some commercial insurance plans and employer plans now cover Zepbound for weight management. Medicare Part D can cover Zepbound for obstructive sleep apnea, and since July 1, 2026 eligible beneficiaries can get the Zepbound KwikPen for weight management through the Medicare GLP-1 Bridge for a $50 monthly copay. If your plan covers it, your copay depends on the plan. Check our insurance coverage guide for tips on getting approved.

How much weight can I lose on Zepbound?

In the SURMOUNT-1 clinical trial, participants on the 15 mg dose lost an average of 20.9% of their body weight over 72 weeks. In the SURMOUNT-5 head-to-head trial against semaglutide, tirzepatide produced 20.2% weight loss. Individual results vary based on dose, diet, exercise, and other factors.

Is compounded tirzepatide the same as Zepbound?

Compounded tirzepatide contains the same active molecule as Zepbound. The difference is that the compounded version is mixed by a licensed compounding pharmacy rather than manufactured by Eli Lilly. Compounded products have not gone through FDA review. The tirzepatide shortage ended in October 2024, so routine compounded copies lost their legal basis in 2025. Our compounded vs brand-name guide covers the tradeoffs in detail.

Should I choose Zepbound or Wegovy?

If maximum weight loss is your priority and you can access both, Zepbound (tirzepatide) has stronger clinical data. The SURMOUNT-5 trial showed 47% more weight loss with tirzepatide compared to semaglutide. If you have heart disease, Wegovy has the SELECT trial showing a 20% reduction in major cardiovascular events in people without diabetes. Cost and insurance coverage often end up being the deciding factor for most people.

Last updated: November 2026. Pricing and availability may change. This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.

What we checked

This AI-assisted public-source desk check reviewed the Zepbound FDA label, the SURMOUNT-1 and SURMOUNT-5 publications, the SELECT publication, the LillyDirect Zepbound self-pay page, the CMS Medicare GLP-1 Bridge page, and the FDA compounding policy page on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.